Idarubicin Hydrochloride Ahp
Idarubicin Hydrochloride Ahp Uses, Dosage, Side Effects, Food Interaction and all others data.
An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.
Idarubicin Hydrochloride Ahp is an antineoplastic in the anthracycline class. General properties of drugs in this class include: interaction with DNA in a variety of different ways including intercalation (squeezing between the base pairs), DNA strand breakage and inhibition with the enzyme topoisomerase II. Most of these compounds have been isolated from natural sources and antibiotics. However, they lack the specificity of the antimicrobial antibiotics and thus produce significant toxicity. The anthracyclines are among the most important antitumor drugs available. Doxorubicin is widely used for the treatment of several solid tumors while daunorubicin and idarubicin are used exclusively for the treatment of leukemia. Idarubicin Hydrochloride Ahp may also inhibit polymerase activity, affect regulation of gene expression, and produce free radical damage to DNA. Idarubicin Hydrochloride Ahp possesses an antitumor effect against a wide spectrum of tumors, either grafted or spontaneous. The anthracyclines are cell cycle-nonspecific.
| Trade Name | Idarubicin Hydrochloride Ahp |
| Availability | Prescription only |
| Generic | Idarubicin |
| Idarubicin Other Names | 4-Demethoxydaunorubicin, Idarubicin, Idarubicina, Idarubicine, Idarubicinum |
| Related Drugs | Venclexta, prednisone, methotrexate, dexamethasone, triamcinolone, Decadron, Keytruda, hydroxyurea, pembrolizumab, vincristine |
| Weight | 10mg/ml |
| Type | Injection |
| Formula | C26H27NO9 |
| Weight | Average: 497.4939 Monoisotopic: 497.168581467 |
| Protein binding | 97% |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | Al-habib Pharmaceuticals, |
| Available Country | Pakistan |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Idarubicin Hydrochloride Ahp is an anthracycline antineoplastic agent used to treat acute myeloid leukemia (AML) in adults.
For the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7.
Idarubicin Hydrochloride Ahp is also used to associated treatment for these conditions: Acute Myeloid Leukemia (AML)
How Idarubicin Hydrochloride Ahp works
Idarubicin Hydrochloride Ahp has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: Idarubicin Hydrochloride Ahp forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes.
Food Interaction
No interactions found.Idarubicin Hydrochloride Ahp Drug Interaction
Moderate: cytarabine, cytarabine, filgrastim, filgrastimMinor: sulfamethoxazole / trimethoprim, sulfamethoxazole / trimethoprimUnknown: diphenhydramine, diphenhydramine, meperidine, meperidine, epoetin alfa, epoetin alfa, enoxaparin, enoxaparin, gemtuzumab, gemtuzumab, acetaminophen, acetaminophen, azacitidine, azacitidine
Idarubicin Hydrochloride Ahp Disease Interaction
Major: infections, heart disease, hepatic dysfunction, myelosuppression, renal dysfunctionModerate: hyperuricemia
Half Life
22 hours
Elimination Route
The drug is eliminated predominately by biliary and to a lesser extent by renal excretion, mostly in the form of idarubicinol.
Innovators Monograph
You find simplified version here Idarubicin Hydrochloride Ahp
